Introduction
Ubiquitin-mediated proteolysis plays a key role in the regulation of the cell cycle. The anaphase-promoting complex/ cyclosome (APC/C) has been identified as the ubiquitin ligase that mediates the degradation of mitotic cyclins (King et al, 1995; Sudakin et al, 1995) . About 20 different cell cycle proteins have been identified so far as APC/C degradation substrates (Harper, 2002; Peters, 2002) .
The APC/C is active in a cell cycle-specific manner from metaphase until the end of G1. APC/C activity is regulated by phosphorylation of several of its subunits (Shteinberg et al, 1999; Kramer et al, 2000; Rudner and Murray, 2000; Golan et al, 2002) , as well as by the association with Cdc20/fizzy or Cdh1/Hct1/fizzy related. Cdc20 is an essential protein, which is required for the activation of the APC/C in mitosis (Sigrist et al, 1995; Visintin et al, 1997) . Cdc20 associates with the APC/C in its phosphorylated form (Shteinberg et al, 1999; Kramer et al, 2000; Rudner and Murray, 2000) and is required for the degradation of mitotic APC/C substrates like cyclins A and B, securin and Xkid. Cdh1 (Schwab et al, 1997; Sigrist and Lehner, 1997; Visintin et al, 1997) is required for the activation of the APC/C during G1 (Hagting et al, 2002; Zur and Brandeis, 2002) . The APC/C Cdh1 can target all the substrates of the APC/C Cdc20 , and in addition targets several other specific substrates that are not targeted by the APC/ C Cdc20 . The observation that Cdc20 and Cdh1 determine the substrate specificity of the APC/C has suggested that they serve as adaptor proteins that bind the different degradation substrates. This hypothesis has been supported by several observations of direct interaction between Cdc20 and Cdh1 and degradation substrates (Burton and Solomon, 2001; Hilioti et al, 2001; Pfleger et al, 2001a; Schwab et al, 2001) . Intriguing recent experiments in mitotic Xenopus extracts have, however, shown that substrates can remain in complex with the APC/C without Cdc20 (Yamano et al, 2004) . This interaction could possibly be mediated by APC10 (Vodermaier et al, 2003) .
The activity of the APC/C is regulated in a very tight and complex manner, as would be expected from such an important element of the cell cycle. Auto-regulation is a central motif in the regulation of the APC/C. Many of the proteins that play a role in the activation and inhibition of the APC/C are themselves subsequently degraded by it. Both cyclin B1 and Plk1 (Shteinberg et al, 1999; Golan et al, 2002; Kraft et al, 2003) , which phosphorylate the APC/C so that it can bind Cdc20 in prometaphase, are subsequently degraded by the APC/C. Cdc20 itself is degraded by the APC/C Cdh1 (Shirayama et al, 1998; Pfleger and Kirschner, 2000) , as is also E2-C, one of the ubiquitin-conjugating enzymes that interacts with the APC/C (Yamanaka et al, 2000) .
Cdh1 is a potent APC/C activator. In contrast to Cdc20, which can bind the APC/C only when it is phosphorylated by mitotic kinases, Cdh1 can activate the APC/C any time. This makes Cdh1 a potentially dangerous and toxic cell cycle protein that must be tightly regulated. Cdh1 is indeed regulated at multiple levels. Its transcription and mRNA stability are both cell cycle specific (Inbal et al, 1999) . During the S phase, as well as during G2 and the early stages of mitosis, Cdh1 is inactivated by phosphorylation by cyclin A2-cdk2 and cyclin B1-Cdk1 (Lukas et al, 1999; Listovsky et al, 2000) . The inactivation of the APC/C Cdh1 at the end of G1 is mediated by Emi1, which binds Cdh1 and turns off APC/ C Cdh1 activity (Hsu et al, 2002) . Phosphorylation of Cdh1 by cyclin A2-cdk2 in S phase prevents the re-association of Cdh1 with the APC/C. Relatively moderate overexpression of Cdh1 is sufficient for preventing its inactivation at G1/S, leading to severe cell cycle effects both in yeast, Drosophila and in mammalian cells (Schwab et al, 1997; Sigrist and Lehner, 1997; Visintin et al, 1997; Sorensen et al, 2000) . Cdh1 levels have been shown to decline during G1 , but the nature of this regulation is unknown. We show here that mammalian Cdh1 is degraded in G1 and G0 and that this degradation is mediated by Cdh1-activated APC/C.
Results

Cdh1 levels oscillate during the cell cycle
To characterize the changes of Cdh1 levels during the mammalian cell cycle, we synchronized mouse NIH3t3 fibroblasts in prometaphase by nocodazole treatment for 16 h. The arrested cells were obtained by mitotic shake-off and either harvested immediately or released into fresh medium to proceed with the cell cycle. Cells were harvested at different times throughout the cell cycle. Cell synchronization was verified by probing the extracts with an antibody for cyclin B1, which is known to be degraded upon exit from mitosis and to re-accumulate upon entry into the S phase 8-10 h later (Brandeis and Hunt, 1996) . These extracts were then probed with a Cdh1-specific antibody. Figure 1A shows that Cdh1 levels declined gradually during early G1 and reached minimal levels in late G1 about 8 h after release from nocodazole. This result was somewhat puzzling given the fact that Cdh1 is active during this phase of the cell cycle (Zur and Brandeis, 2002) . The slightly shifted bands of Cdh1 in nocodazolearrested and S-phase extracts show that Cdh1 is phosphorylated from S phase to mitosis. This phosphorylation is known to prevent its association with, and activation of, the APC/C (Lukas et al, 1999; Listovsky et al, 2000) .
We next studied the levels of Cdh1 in serum-starved G0 arrested cells. Cells arrested in G0 have an active APC/C Cdh1 (Brandeis and Hunt, 1996) . Figure 1B shows that in G0, levels of Cdh1 are low and they rise about 15 h after stimulation with serum, a time point that coincides with late G1. Figure 1C shows the quantiation of Cdh1 versus actin levels at different times of the cell cycle. The levels of Cdh1 in G1 and G0 cells is only 40 and 30%, respectively, of that of nocodazole-arrested cells. The absolute levels of Cdh1 are probably even lower, as actin also declines in serum-starved cells.
We have previously shown that Cdh1 binds the APC/C throughout G1, until the entry into S phase (Zur and Brandeis, 2001 ). We therefore used gel filtration to study the amount of free and APC/C-associated Cdh1 in the cell at different phases of the cell cycle. Cells were either arrested by nocodazole in prometaphase, released from nocodazole into G1, or arrested in G0 by serum starvation. Cell extracts were loaded onto a Sephacryl S200 gel filtration column, and the eluted fractions were immunoblotted with antibodies for Cdh1 and for the APC/C subunit Cdc27. Figure 2A shows that in G1 and G0 most of the Cdh1 co-eluted from the column with the large APC/C complex. In prometaphase, in contrast, Cdh1 did not co-elute with the APC/C but in lower molecular weight fractions, suggesting that it is monomeric and not bound to the APC/C. A side-by-side comparison of Cdc27 from the different phases shows the mitotic phosphorylation of Cdc27 ( Figure 2B ).
Cdh1 is degraded in G1 in G0
The significant reduction of Cdh1 levels during G1 suggested that it is degraded. To address this question, we synchronized cells with nocodazole in prometaphase and released them into G1. Cells were treated with the protein synthesis inhibitor cyclohexamide (100 mg/ml), 1 h after release from nocodazole. Treated and untreated cells were harvested after an additional 2 and 5 h. Figure 3 shows that by 3 h the amount of Cdh1 was reduced by two-thirds in the presence of the inhibitor and only by a third in its absence. By 6 h, most of the Cdh1 was degraded also in the absence of the inhibitor, probably because it was no longer transcribed (Inbal et al, 1999) . These observations suggest that Cdh1 is indeed degraded with an approximate half-life of about 1 h.
In order to examine Cdh1 degradation in more detail, we fused different parts of Cdh1 to the Chloramphenicol Acetyl Transferase (CAT) reporter gene. We stably expressed expression vectors for Cdh-CAT in NIH3t3 cells and studied their cell cycle-specific CAT activity. We used this CAT-based assay to study the degradation of various proteins in the past (Zur and Brandeis, 2002) . Figure 4A shows that a fusion protein comprising the N-terminal 180 amino acids of Cdh1 and CAT was stable in mitosis and degraded in G1. Wild-type CAT, in contrast, did not change at all during the cell cycle in accordance with the high stability of this protein. Cells expressing the Cdh-CAT and wt CAT expression vectors were also arrested in G0 by serum starvation and their CAT activity was monitored as they were stimulated with serum to re-enter the cell cycle. Cdh-CAT activity was very low in G0 and rose only after 15 h when cells approached the S phase. Wt CAT was again stable throughout the experiment ( Figure 4B ). Fusion constructs with less than 180 amino acids were also tested but were not degraded (data not shown).
Cdh1 has two RXXL destruction boxes and is degraded by the APC/C
The only known cell cycle-specific proteolysis mechanism in G1 and G0 is the APC/C. We wondered therefore whether Cdh1 could be degraded by the APC/C. This might have been a somewhat paradoxical hypothesis as Cdh1 is also the sole known activator of the APC/C during G1 and G0. We examined the sequence of Cdh1 and identified two motifs RRLLRQIVI and RRTLTPASS (single-letter amino-acid code) that have the two essential residues (R and L) of the RXXL destruction box. This RXXL box is one of the two known motifs that targets substrates for degradation by the APC/C. We termed these putative RXXL destruction boxes DB1 and DB2.
We used site-directed mutagenesis to change the R and L residues of either or both of DB1 and DB2 to make DM1, DM2 and DM1 þ 2, respectively ( Figure 5A ), and studied the degradation of the mutated fusion proteins in G1. Figure 5B shows that mutating either or both of these RXXL motifs completely abolished the degradation of the fusion proteins.
The addition of sequences upstream of destruction boxes also often interferes with degradation. We therefore tested the degradation of Cdh-CAT N-terminally tagged with a single myc tag. Figure 5B shows that this construct was completely stable. This result is of particular interest as overexpression of moderate levels of myc-Cdh1 lead to a particularly severs phenotype (Sorensen et al, 2000) .
We used an in vitro ubiquitilation assay with purified APC/ C and in vitro transcribed and translated full-length wild-type or destruction box mutant Cdh1 as substrates. Figure 5C shows that Cdh1 was highly ubiquitylated and that mutations of either DB1, or DB2, almost completely abolished this ubiquitylation.
To follow degradation of Cdh1 in real time, we generated expression vectors encoding the 180 N-terminal amino acids of Cdh1 and the double destruction box mutant Cdh1-DM1 þ 2 to Yellow Fluorescent Protein (YFP). We injected these vectors into cells and followed expressing cells by timelapse photography. Figure 5D shows that the fluorescence of cells that express Cdh-YFP gradually declines after mitosis throughout G1. Cells expressing Cdh-DM1 þ 2-YFP, in contrast, remain fluorescent throughout the cell cycle.
Cdh1 is degraded by the APC/C
Cdh1 and not by the APC/C
Cdc20
The APC/C in mammalian cells can be activated either by Cdc20 or by Cdh1. Activation of the APC/C by Cdc20 takes place in mitosis. Cdc20 is dissociated from the APC/C upon exit from mitosis and is degraded by Cdh1-activated APC/C. The APC/C Cdh1 is capable of targeting all the substrates of the APC/C Cdc20 as well as several additional substrates. We used several assays to examine whether Cdh1 is degraded by both the APC/C Cdc20 and the APC/C Cdh1 , or only by the APC/C
Cdh1
. We transfected cells stably expressing fusion reporter vectors with an expression vector of nondegradable cyclin B1. Cyclin B1-Cdk1 inactivation is essential for cells to exit mitosis and nondegradable cyclin B1 arrests cells in mitosis (Wheatley et al, 1997; Stemmann et al, 2001) . Cyclin B1-Cdk1 phosphorylates Cdh1 and prevents it from binding and activating the APC/C . Cells are thus arrested in mitosis with a highly active APC/ C Cdc20 . Several APC/C Cdc20 and APC/C Cdh1 substrates tested by this method have shown that only APC/C Cdc20 substrates are degraded under these conditions (Hagting et al, 2002; Zur and Brandeis, 2002) . This is so far the only in vivo test in mammalian cells for APC/C Cdc20 -specific degradation. Figure 6A shows that while the cyclin B1-CAT fusion reporter is degraded in these cells, Cdh-CAT remains stable. Both reporters are degraded in G1. This assay suggests that Cdh1 is not an APC/C Cdc20 substrate. The only other APC/C activator known so far in mammals is Cdh1 itself, so that it is possible to assume that the APC/ C Cdh1 is degrading Cdh1. To test this hypothesis in a more direct manner, we co-transfected cells with a Cdh1 expression vector together with fusion reporters. Cells were then arrested with nocodazole in prometaphase. We have previously shown that the checkpoint-arrested APC/C in nocodazolearrested cells can be activated by Cdh1 overexpression . Figure 6B shows that Cdh-CAT, as well as cyclin B1-CAT, was effectively degraded in these cells. The Cdh1-DM1 mutant, in contrast, was not degraded. The APC/C Cdh1 can be activated in prometaphase-arrested cells also by chemical inhibition of Cdk1 kinase activity . We arrested cells stably expressing fusion reporters in prometaphase with nocodazole and treated them with the Cdk1 inhibitor roscovitin. Figure 6C shows that roscovitin induced the degradation of both Cdh-CAT and cyclin B1-CAT, but not of CAT.
We addressed Cdh1 degradation also in Xenopus egg interphase extracts. Xenopus eggs lack a G1 phase and do not express Cdh1 (Lorca et al, 1998) . We prepared interphase extracts by standard methods (Murray, 1991) and used them for degradation assays. As a substrate, we used Schizosaccharomyces pombe cyclin B (cdc13) in parallel with its nondegradable N-terminal deletion mutant D67, which served as a loading control and a control for nonspecific degradation. Figure 7A shows that, as expected, the interphase extract did not degrade cyclin B. When we added Cdh1, or its destruction box mutant, to the interphase extracts, cyclin B was degraded. The C-terminal arginine residue of Cdh1 is required for its binding and activating of the APC/C (Vodermaier et al, 2003) . We therefore generated a Cdh1 mutant with a deleted c-terminal arginine (Cdh1-R). Adding Cdh1-R to the interphase extract failed, as expected, to activate the APC/C to degrade cyclin B. Figure 7B shows that when Cdh1 was added to the interphase extracts it was degraded. A destruction box mutant of fzr was considerably stabilized and the Cdh1-R was completely stable. The observation that Cdh1, which activates the APC/C, is degraded, while Cdh1-R, which does not activate the APC/C, is not degraded, suggests that Cdh1 degradation is indeed autoregulated.
In a further set of experiments, we prepared interphase extracts, treated them with RNAse and subsequently inhibited RNAse activity (Murray, 1991) . To these extracts, we added Cdh1 mRNA and allowed it to be translated for 1 h. [ 35 S]methionine added to an aliquot of these extracts showed that Cdh1 was efficiently translated (not shown). Figure 7C shows that Cdh1-activated interphase extracts efficiently degrade cyclin B and securin but, as expected, not cyclin B-D67. Surprisingly, neither Cdh1 nor Cdh1-R was degraded in these extracts, which were pre-activated with Cdh1. It is thus possible that the Cdh1 bound already to the APC/C competitively inhibited the interaction and degradation of the labeled Cdh1 that we added to the reaction.
Discussion
Many cellular pathways are regulated by ubiquitin-mediated proteolysis. An essential characteristic of such a regulation is its high substrate specificity. Cell cycle regulation by proteolysis is further characterized by high temporal specificity. The APC/C has three different states-it is inactive from S phase until metaphase, it has a Cdc20-specific activity from metaphase until telophase and a Cdh1-specific activity during G1. The APC/C is a large complex of about a dozen different subunits; however, almost all the mechanisms that regulate its activity, discovered so far, focus on the availability and binding of Cdc20 and Cdh1. The binding of Cdc20 requires the phosphorylation of several subunits, which takes place only in mitosis (Kramer et al, 1998; Shteinberg et al, 1999; Rudner and Murray, 2000; Kraft et al, 2003) . Cdc20 is negatively regulated by phosphorylation (Yudkovsky et al, 2000) , by binding of checkpoint proteins (Fang et al, 1998; Sudakin et al, 2001; Tang et al, 2001) , by Emi1 (Reimann et al, 2001) and by APC/C Cdh1 -specific degradation (Shirayama et al, 1998; Pfleger and Kirschner, 2000) . Cdh1 is regulated by transcriptional regulation and mRNA stability (Inbal et al, 1999) , by phosphorylation Lukas et al, 1999; Listovsky et al, 2000) , by Emi1 (Hsu et al, 2002) and by Mad2l2/Mad2B (Chen and Fang, 2001; Pfleger et al, 2001b) . We show here that Cdh1 is further negatively regulated by its own degradation by the APC/C Cdh1 (Figures 5-7) . These different inhibitory mechanisms play different roles during different phases of the cell cycle. Cdh1 is negatively regulated by phosphorylation during S, G2 and early mitosis, by Mad2l2 during mitosis, by proteolysis during G1 and by Emi1 at the transit from G1 to S.
The regulation of Cdh1 levels is of great importance and its overexpression is toxic to the cell cycle. Drosophila fzr overexpression downregulates mitotic cyclins in epidermal cells, inhibits mitosis and leads to endoreplication cycles (Sigrist and Lehner, 1997) . Moderate overexpression of Cdh1 in mammalian cells leads to constitutive degradation of APC/ C substrates, failure to enter mitosis and over-replication of DNA (Sorensen et al, 2000) . We show here that the myctagged version used in these experiments might be no longer degraded by the APC/C ( Figure 5B ). This result suggests that degradation of Cdh1 could play a role in regulating the levels of Cdh1 and switching off the APC/C Cdh1 . In addition to the RXXL boxes, at least 180 N-terminal amino acids are required for Cdh1 degradation; additional deletions completely stabilized the protein (data not shown).
Other APC/C substrates that we tested always required less than 100 residues. It has been shown that a 173 residue long N-terminal fragment of Cdh1 binds to the APC/C but that shorter fragments do not bind (Pfleger et al, 2001a) . It is thus possible that Cdh1 must bind the APC/C in order to be degraded. This possibility is further supported by the observation that a surplus of unlabeled Cdh1 inhibits the degradation of labeled Cdh1, but not that of other APC/C substrates ( Figure 7C ). This competitive inhibition does not depend on an intact RXXL box of the inhibitor (data not shown). In other reported cases of competitive inhibition of APC/C by a surplus of substrate (Holloway et al, 1993; Yamano et al, 1998) , inhibition depended on an intact RXXL box and inhibited the degradation of different substrates. The possible requirement for Cdh1 binding to the APC/C for it to be degraded would be similar to what has been observed for the F-box protein Skp2, which is degraded by auto-ubiquitylation (Wirbelauer et al, 2000) .
An interesting aspect of Cdh1 degradation is the fact that it requires both RXXL boxes. Several APC/C substrates carry more than one functional d-box. Human securin has both a KEN and an RXXL box, but each box can drive degradation on its own (Zur and Brandeis, 2001) . Drosophila securin (pim1) also has both a KEN and an RXXL box, and both are required for degradation (Leismann and Lehner, 2003) . Complex degradation signals have also been reported for Drosophila cyclin A (Jacobs et al, 2001) . To the best of our knowledge, however, Cdh1 is the first mammalian APC/C substrate that has two functional RXXL boxes that are both required for degradation. Unfortunately, this adds to the prevailing mystery of the role and function of RXXL boxes.
The F-box protein Skp2, which confers substrate specificity to the SCF (Skp2, Cul1, F box) E3 ubiquitin ligase complex, also mediates its own degradation (Wirbelauer et al, 2000) . Cdh1 is a substrate specificity factor of the APC/C and therefore plays a role somewhat analogous to that F-box proteins. A mechanism of regulating protein levels by selfdegradation might sound somewhat paradoxical, but it is in principle the most reliable and foolproof negative feedback method imaginable. If all what is required for keeping Cdh1 levels low is Cdh1 activity, then no failure of any other protein can lead to a rise in Cdh1 activity. In case any component of the APC/C Cdh1 pathway fails, Cdh1 levels might rise, but as the APC/C Cdh1 is inactive this will cause no problems. Indeed, the level of Cdh1 is higher when it is inactive in mitosis, but as it is inactive this can cause no harm. The auto-regulatory mechanism of Cdh1 is thus the ultimate way of keeping APC/C Cdh1 activity at exactly the desired level. This level will be high enough to activate the APC/C in G1, and low enough to enable it to be switched off at the end of G1. It is further possible that this mode of regulation enables high levels of APC/C Cdh1 activity during exit from mitosis and early G1 and reduced activity later in G1. This might reflect the requirement of degrading a large number of cdh1 substrates after cell division, compared to a lower APC/C activity required for G1 maintenance.
Materials and methods
Expression vectors
The sequence coding for the N-terminal 180 amino acids of human Cdh1 was amplified by PCR and cloned into pSV-CAT (Brandeis and Hunt, 1996) upstream of and in frame with the CAT gene. Cdh-YFP was made by cloning the same sequence into pEYFP-C1 (Clontech) upstream of and in frame with the EYFP gene. KS-Cdh1 was made by cloning the full-length Cdh1 gene into Bluescript-KSII downstream of the T7 promoter. All point mutations were performed by the quickchange method (Stratagene). Vectors expressing Cdh1, nondegradable cyclin B1 and human securin have previously been described Zur and Brandeis, 2001 ). Cdc13 and its stable N-terminal deletion mutant cdc13D67 were a kind gift from Hiro Yamano (Yamano et al, 1998) .
Cell culture, transfections, synchronization and CAT assays All the experiments were performed in NIH3t3 mouse fibroblasts. Cells were maintained in DMEM supplemented with glutamine, pens/strep and 10% fetal calf serum (FCS, Beit Haemek) and transfected by the CaPO 4 co-precipitation method (Ausubel et al, 1994) . The various CAT fusion expression vectors were cotransfected with a G418 resistance vector, and resistant colonies were pooled. Prometaphase-arrested cells were obtained by shakeoff and were processed for CAT assay or immunoblotting. Stable transfectants were either synchronized by nocodazole and shake-off or by serum deprivation in 0.5% FCS for 48 h. The former were washed and released into fresh medium without nocodazole and the latter were released with 10% FCS.
All the experiments, except those in Figure 6B , were performed with stably transfected lines to prevent fluctuations due to transfection efficiency. For the experiment shown in Figure 6B , cells were co-transfected with the various plasmids, as described under Results. They were incubated overnight with the precipitate, washed the following morning, were allowed to recover for several hours and were treated with nocodazole for about 16 h.
Nocodazole (Sigma-2 mM) and roscovitin (Biomol-28 mM) were dissolved in DMSO. CAT assays were performed by standard methods (Ausubel et al, 1994) 
Antibodies
Monoclonal antibodies to Cdh1 were a kind gift from Julian Gannon (ICRF, London). Hybridoma supernatant was used for Western blotting. Cdc27 monoclonal antibodies were purchased from transduction laboratories (C40920) and goat anti-actin antibodies from Santa Cruz Biotechnology (#SC-1616); both were used at a 1:1000 dilution.
Gel filtration
Cell extracts were prepared from synchronized cells in 20 mM TrisHCl (pH 7.5), 100 mM NaCl, 20 mM b-glycerophosphate, 1 mM NaF, 0.5 mM DTT, 10% glycerol and 0.2%NP-40 (Vodermaier et al, 2003) . The samples were fractionated on a 300 Â10 mm Sephacryl S200 gel filtration column with extraction buffer, on an AKTA Explorer system (Amersham Biosciences) at 1 ml/min. Fractions (1 ml) were collected after 0.3 column volumes. In all, 20 ml of each sample was resolved by SDS-PAGE and immunoblotted with Cdc27 and Cdh1 antibodies.
Injection and time lapse
NIH3t3 cells were plated on 35 mm plates and injected with an AIS2 (cell biology trading) computer-assisted microinjection setup. Cells were followed on an IX70 inverted Olympus microscope fitted with a heated stage, two filter wheels (Sutter) and a Magnafire CCD camera (Optronics). The cells were viewed using a YFP filter (Chroma) and the Magnafire was used in the monochrome mode. The entire setup was controlled using a macro-program developed in-house and running under ImagePro version 4.5 and ScopePro version 4 (Media Cybernetics).
In vitro ubiquitylation assays
The in vitro ubiquitylation assays were performed as previously described (Yudkovsky et al, 2000) . The substrates of ubiquitylation were prepared by in vitro transcription and translation of KS-Cdh1 and its mutant derivatives, KS-Cdh1-DM1 and KS-Cdh1-DM2, in a coupled reticulocyte lysate system (Promega) in the presence of [ 35 S]methionine. Each reaction contained partially purified APC/C, E1, E2-C and an energy-regenerating system.
Degradation assays in Xenopus interphase extracts
Xenopus egg interphase extracts were prepared as previously described (Murray, 1991) . Fresh extracts were treated with RNAse (1 ng/ml) for 15 min at 101C. RNAse was inactivated by adding the RNAsin RNAse inhibitor (3 units/ml, Amersham) for 10 min at 101C. Cdh1 mRNA, transcribed from a T7 promoter with an mMassage mMachine kit (Ambion), was added to the extract (approximately 20 ng/ml) and allowed to translate for 1 h at 231C. The extract was then aliquoted and snap frozen in liquid nitrogen. To follow Cdh1 synthesis, a 5 ml aliquot was removed immediately after adding the mRNA and mixed with 1 ml of [
35 S]methionine þ cystein (Promix, Amersham). The labeled Cdh1 was analyzed by gel electrophoresis.
Substrates for destruction assays were synthesized in a coupled in vitro transcription-translation reaction mix (TNT, Promega) in the presence of [
35 S]methionine þ cystein. For destruction assays, extracts were first treated with cyclohexamide (0.1 mM) for 10 min at 231C. Subsequently, 0.5 ml of substrate was added to 10 ml of interphase extract (either with or without Cdh1) and incubated at 231C. Aliquots of this reaction were removed at the indicated time points and resolved by PAGE.
